A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

MLA

Sophie Leboulleux, et al. “A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.” Clinical Cancer Research, May 2023, pp. OF1-OF9. EBSCOhost, https://doi.org/10.1158/1078-0432.ccr-23-0046.

APA

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, Ludovic Lacroix, Danielle Benisvy, David Taïeb, Stéphane Bardet, Marie Terroir-Cassou-Mounat, Nadège Anizan, Emilie Bouvier-Morel, Livia Lamartina, Georges Lion, Sarah Betrian, Christophe Sajous, Aurélie Schiazza, Marie-Eve Garcia, Renaud Ciappuccini, … Isabelle Borget. (2023). A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer. Clinical Cancer Research, OF1-OF9. https://doi.org/10.1158/1078-0432.ccr-23-0046

Chicago

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, Ludovic Lacroix, Danielle Benisvy, et al. 2023. “A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.” Clinical Cancer Research, May, OF1-OF9. doi:10.1158/1078-0432.ccr-23-0046.